A practical reference on pineal peptides: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-07. Anything still debated is marked as such rather than presented as settled.
The four residues give epitalon a molecular formula of C14H22N4O9 and a molecular weight near 390.35 daltons. The presence of two acidic residues, glutamate and aspartate, makes the free peptide strongly acidic, while the alanine and glycine ends provide neutral, nonpolar character. This combination produces a molecule with substantial water solubility. Because there are no cysteine, methionine, or tryptophan residues, the peptide lacks the most common oxidation-sensitive side chains, which simplifies handling compared with many longer peptides.
The proposed relationship between epitalon and pineal function is a central part of its background. Khavinson's group reported that short peptides corresponding to regions of larger pineal proteins could influence gene expression in cells. Epitalon was framed as a synthetic analogue of an active fragment rather than a direct isolation product. Whether the tetrapeptide reproduces the effects of the parent extract is an open question, because comparative studies are limited and the parent extract itself is not a single defined substance.
Interest in epitalon is usually discussed within the broader field of short peptide bioregulators, a category that includes other synthetic di-, tri-, and tetrapeptides studied by the same research group. These compounds share a common rationale: that small fragments of tissue-derived proteins can retain biological activity and can be produced reproducibly. The category as a whole remains outside mainstream pharmacological consensus, and epitalon specifically has a limited presence in independent, non-Russian research literature, which shapes how its evidence base is described.
Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.
The peptide is a synthetic analogue of epithalamin, a preparation extracted from bovine pineal glands. Investigators sought a short, chemically defined molecule that would reproduce some of the endocrine and gerontological observations attributed to the glandular extract. Proposed mechanisms centre on induction of telomerase activity, an effect reported in cultured human somatic cells in the early 2000s, together with influences on melatonin secretion and neuroendocrine regulation. Those mechanisms remain incompletely characterised, and the reported telomerase response has not been consistently reproduced by independent groups working in comparable systems.
Published work on this compound consists mainly of in vitro experiments, animal studies, and small clinical investigations, a substantial share of which appeared in Russian-language journals. Sample sizes are generally small, control conditions differ between studies, and several endpoints rely on markers whose clinical meaning is itself debated. Reviews of the longevity field treat the peptide as an early example of telomerase-directed research rather than an established intervention. Regulatory treatment varies by country: some jurisdictions place it under prescription controls, others treat it as a laboratory material, and importation may be restricted regardless of local status.
| Property | Value | Notes |
|---|---|---|
| Amino acid sequence | Ala-Glu-Asp-Gly | Tetrapeptide, often abbreviated AEDG |
| Molecular formula | C14H22N4O9 | Free peptide, unmodified termini |
| Molecular weight | ~390.35 Da | Calculated for the free acid form |
| Appearance | White to off-white powder | Typical lyophilized product form |
| Solubility class | Freely soluble in water | Two acidic residues dominate ionic character |
Epitalon is the common name for a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, usually abbreviated AEDG. All four residues are proteinogenic amino acids, and the free peptide has a calculated mass near 390 grams per mole. Because the chain is short and carries no modifications, it is assembled readily by solid-phase synthesis and is distributed mainly as a freeze-dried solid for laboratory work. Catalogue listings use the spellings epitalon, epithalone, and simply AEDG, and the three refer to the same sequence.
The compound is generally presented as a synthetic fragment of epithalamin, a pineal gland extract investigated in the former Soviet Union from the 1970s onward. Vladimir Khavinson and colleagues in Saint Petersburg developed short peptides modelled on such extracts, and epitalon became the most widely cited of those sequences. Most primary reports appeared in Russian-language journals or in proceedings with limited international circulation. Independent replication in laboratories outside that network remains sparse, and much repeated secondary material traces back to a small number of originating groups.
Laboratory work has examined effects on telomerase activity in cultured cells, on melatonin rhythms in animals, and on markers of oxidative stress. Some experiments report measurable changes while others show none, and the reported findings rest largely on small studies. The absence of large independent trials means the generality of these results is unresolved rather than settled. Review articles occasionally apply the label geroprotector, a term that reflects a research hypothesis about ageing rather than an established clinical finding.
== Clinical significance == Some can be useful in measuring rates of metabolic processes (for example, 3,4-dihydroxyphenylacetic acid or 3-aminoisobutyrate). Because they can represent unnatural points of entry into natural metabolic pathways, some (such as AICA ribonucleotide) are of interest to researchers in developing new therapies.
=== Protein complementation assays and interaction screens === Protein-fragment complementation assays are often used to detect protein–protein interactions. The yeast two-hybrid assay is the most popular of them but there are numerous variations, both used in vitro and in vivo. Pull-down assays are a method to determine the protein binding partners of a given protein.
==== Attention deficit hyperactivity disorder (ADHD) ==== A meta-analysis of observational studies showed that children with ADHD have lower vitamin D levels and that there was a small association between low vitamin D levels at the time of birth and later development of ADHD. Several small, randomized controlled trials of vitamin D supplementation indicated improved ADHD symptoms such as impulsivity and hyperactivity.
Sources: en.wikipedia.org
=== Sodium channels === AM404 has also been reported to inhibit voltage-gated sodium channels in the peripheral nervous system, with much greater potency than its effects at previously proposed targets. Specifically, it inhibits Nav1.8 and 1.7 channels at nanomolar concentrations in vitro. AM404 injected into the hind paw of rats increase the pain threshold for the treated paw, but not the untreated paw, confirming the peripheral nature of this effect. It also lowers pain responses in a few other in vivo models when injected directly into the affected area. Other tested metabolites of paracetamol do not block pain-sensing sodium channels in vitro.
Nihonium is a synthetic chemical element; it has symbol Nh and atomic number 113. It is extremely radioactive: its most stable known isotope, nihonium-286, has a half-life of about 10 seconds. In the periodic table, nihonium is a transactinide element in the p-block. It is a member of period 7 and group 13. Nihonium was first reported to have been created in experiments carried out between 14 July and 10 August 2003, by a Russian–American collaboration at the Joint Institute for Nuclear Research (JINR) in Dubna, Russia, working in collaboration with the Lawrence Livermore National Laboratory in Livermore, California, and on 23 July 2004, by a team of Japanese scientists at Riken in Wakō, Japan. The confirmation of their claims in the ensuing years involved independent teams of scientists working in the United States, Germany, Sweden, and China, as well as the original claimants in Russia and Japan. In 2015, the IUPAC/IUPAP Joint Working Party recognised the element and assigned the priority of the discovery and naming rights for the element to Riken. The Riken team suggested the name nihonium in 2016, which was approved in the same year. The name comes from the common Japanese name for Japan (日本, Nihon). Very little is known about nihonium, as it has been made only in very small amounts that decay within seconds. The anomalously long lives of some superheavy nuclides, including some nihonium isotopes, are explained by the island of stability theory.
== History of slow cooking == Long before the invention of electric cooking devices, cultures across Europe, Asia and North Africa relied on heavy cast iron Dutch ovens and pottery, such as the Moroccan tagine. to tenderise tough cuts of meat and simmer pulses over low and sustained heat. These traditional non-electric methods frequently utilised the residual heat of brick hearth ovens or dying wood fires. The mastery of slow cooking stems from a universal culinary challenge: transforming fibrous and collagen rich cuts of meat and hard legumes into digestible and nourishing meals without temperature controls. Across diverse geographies, cooks discovered that sustained and gentle thermal energy breaks down connective tissue over hours. This renders tough ingredients meltingly tender while infusing them with concentrated flavours.
Sources: en.wikipedia.org
A lymph node is divided into compartments called nodules (or lobules), each consisting of a region of cortex with combined follicle B cells, a paracortex of T cells, and a part of the nodule in the medulla. The substance of a lymph node is divided into the outer cortex and the inner medulla. The cortex of a lymph node is the outer portion of the node, underneath the capsule and the subcapsular sinus. It has an outer part and a deeper part known as the paracortex. The outer cortex consists of groups of mainly inactivated B cells called follicles. When activated, these may develop into what is called a germinal center. The deeper paracortex mainly consists of the T cells. Here the T-cells mainly interact with dendritic cells, and the reticular network is dense. The medulla contains large blood vessels, sinuses and medullary cords that contain antibody-secreting plasma cells. There are fewer cells in the medulla. The medullary cords are cords of lymphatic tissue, and include plasma cells, macrophages, and B cells.
There are varied reasons for e-cigarette use. Most users are trying to quit smoking, but some use is recreational or as an attempt to get around smoke-free laws. Many people vape to relax, and some because vaping is safer than smoking. The wide choice of flavors and lower price compared to cigarettes are also important factors. Other motivations include reduced odor and fewer stains. E-cigarettes also appeal to technophiles who enjoy customizing their devices.
The term in situ does not appear in Classical Latin. Its earliest recorded use is in Late Latin, with the first known instance in the writings of Augustine of Hippo (354–430 AD). It became widely used in Medieval Latin. In English, the earliest known usage dates to the mid-17th century; the Oxford English Dictionary cites the first appearance in 1648, in William Molins' anatomical text Myskotomia. The usages in scientific literature increased from the late 19th century onward, initially in medicine and engineering, including geological surveys and petroleum extraction. During this period, the term described analyses conducted within the living human body or inside oil wells, among other applications. In situ entered French medical discourse by 1877 in the Journal de médecine et de chirurgie pratiques ('Journal of Practical Medicine and Surgery'). The compound term carcinoma in situ, referring to abnormal cells that are confined to their original location without invasion of surrounding tissue, was first used in a 1932 paper by U.S. surgical pathologist Albert C. Broders. The concept of in situ in contemporary art developed in the late 1960s and 1970s as a framework for artworks created specifically for a given space. By the mid-1980s, the term was adopted in materials science, particularly in the field of heterogeneous catalysis, where a catalyst in one phase facilitates a chemical reaction in a different phase. Its usage later expanded beyond catalysis and is now applied across various disciplines within materials science.
Sources: en.wikipedia.org
Epitalon is a synthetic tetrapeptide composed of four amino acids: alanine, glutamate, aspartate, and glycine. It is written as Ala-Glu-Asp-Gly. The free peptide has a molecular weight of about 390 daltons and is normally supplied as a lyophilized powder.
No. Epitalon is chemically synthesized, not extracted. It was designed as a short synthetic fragment conceptually related to larger pineal peptides studied in the same research tradition, particularly the extract known as epithalamin. The two are distinct materials with different compositions.
The term bioregulator is used in this research tradition for short peptides proposed to influence gene expression or cell function. Epitalon is grouped with other synthetic short peptides under this label. The term reflects a proposed mechanism rather than an established drug classification.
Epitalon is a synthetic four-amino-acid peptide with the sequence alanine–glutamate–aspartate–glycine, also written AEDG. It was developed in Russian gerontology research and is studied for proposed effects on telomerase, melatonin regulation, and neuroendocrine function. It is not an approved pharmaceutical in the United States or the European Union.